Vimta Labs , a leading testing and research organization, has announced its financial results for the second quarter, showcasing robust growth across key metrics.

Financial Highlights

Revenue Growth

Vimta Labs reported a significant increase in revenue for the second quarter, reaching ₹1,000.00 million, up from ₹847.00 million in the same period last year. This represents a strong year-over-year growth of 18.1%, indicating the company's ability to expand its business and capture market opportunities.

Profitability

The company's net profit also saw a notable improvement, rising to ₹199.00 million from ₹170.00 million in the corresponding quarter of the previous year. This 17.1% increase in net profit demonstrates Vimta Labs' ability to translate revenue growth into bottom-line results.

EBITDA Performance

Vimta Labs' EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew to ₹342.00 million, compared to ₹299.00 million in the prior year period, marking a 14.4% increase. This growth in EBITDA indicates improved operational efficiency and cost management.

Margin Analysis

Despite the overall positive performance, Vimta Labs experienced a slight decline in its EBITDA margin. The EBITDA margin for the quarter stood at 34.20%, down from 35.30% in the same period last year, representing a decrease of 110 basis points. This marginal contraction in margins may be attributed to factors such as increased operational costs or changes in the revenue mix.

The company's ability to maintain a healthy EBITDA margin above 34% while significantly growing its revenue demonstrates its operational resilience and efficient cost management in a potentially challenging business environment.

Conclusion

Vimta Labs' Q2 results reflect a company on a growth trajectory, with substantial improvements in revenue and profitability. The slight margin pressure suggests that the company may need to focus on optimizing its cost structure to fully capitalize on its revenue growth in future quarters.

Vimta Labs Limited , a leading contract research and testing organization, has reported its highest ever quarterly revenue of INR 993.00 million for Q1 FY2026, marking a significant 31.4% year-on-year growth from INR 756.00 million in the same quarter last year.

Financial Highlights

Operational Highlights

• Successfully completed an unannounced US FDA GCP inspection with no Form 483 observations
• Received cGMP compliance letter from ANSM EMA
• Board approved a 1:1 bonus issue
• Completed facility expansion of 200,000 square feet to support future growth
• Maintains a debt-free balance sheet with cash equivalents of INR 379.30 million

Business Segment Performance

Future Outlook

Vimta Labs is progressing with equipment procurement for biologics contract research services, expected to commercialize from Q1 FY2027. The company's expanded facility and strategic investments position it well for future growth across all service offerings.

Ms. Harita Vasireddi, Managing Director of Vimta Labs, commented, "We are pleased to report our highest ever quarterly revenue, putting us on a very strong growth trajectory. The market shifts, emergence of new technologies, and continuous innovation in the pharmaceutical and nutraceutical sectors have significantly heightened the focus on product quality and safety, an area where Vimta is distinctly well positioned."

With its strong financial position, ongoing investments in capacity expansion, and focus on quality and scientific precision, Vimta Labs appears well-positioned to capitalize on the growing demand for contract research and testing services in the pharmaceutical, food, and electronics sectors.

Note: All financial figures are in Indian Rupees (INR).